Nov 11, 2025 • Benzinga
SOMEWHAT-BEARISH
Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile - Neurocrine Biosciences ( NASDAQ:NBIX )
On Monday, Neurocrine Biosciences, Inc. ( NASDAQ:NBIX ) said its Phase 2 study of NBI-1070770 in adults with major depressive disorder did not meet the primary endpoint compared to placebo, though it was generally well tolerated.
Oct 30, 2025 • Benzinga
NEUTRAL
Takeda Lowers 2025 Outlook After Weak Q2 And Pipeline Impairment Charges - Takeda Pharmaceutical Co ( NYSE:TAK )
Takeda Pharmaceutical Company Limited ( NYSE:TAK ) posted a second-quarter 2025 adjusted net profit of 201.6 billion Japanese yen ( approximately $1.31 billion ) . The company reported earnings per American Depositary Share ( EPADS ) of 43 cents, missing analyst expectations of 44 cents.
Oct 14, 2025 • Benzinga
NEUTRAL
Takeda Taps Nabla Bio's Generative AI Platform For Antibody Design In $1 Billion Pact - Takeda Pharmaceutical Co ( NYSE:TAK )
Nabla Bio, a biotechnology company focused on de novo therapeutics design using generative AI, announced a new, multi-year research collaboration on Tuesday with Takeda Pharmaceutical Co., Ltd. ( NYSE:TAK ) .
Oct 10, 2025 • Benzinga
SOMEWHAT-BULLISH
Why Is Protagonist Therapeutics Stock Soaring Friday? - Protagonist Therapeutics ( NASDAQ:PTGX ) , Johnson & Johnson ( NYSE:JNJ )
Johnson & Johnson ( NYSE:JNJ ) is reportedly in discussions to acquire Protagonist Therapeutics ( NASDAQ:PTGX ) . Citing people close to the talks, the Wall Street Journal reported that the deal is not guaranteed, and the terms have yet to be finalized.
Oct 07, 2025 • Benzinga
NEUTRAL
What's Going On With Nano-Cap Galecto Stock On Tuesday? - Galecto ( NASDAQ:GLTO )
Galecto Inc. ( NASDAQ:GLTO ) stock spiked on Tuesday, with a session volume of 61.11 million, compared to the average volume of 984,320, as per data from Benzinga Pro. However, there is no news to justify this extraordinary rally, suggesting speculative trading.
Sep 17, 2025 • Motley Fool
SOMEWHAT-BULLISH
5 Best High-Yield Dividend Stocks to Buy Now
These five dividend stocks yield between 3.5% and 7.1%, but more importantly, they have the cash flows and business models to keep paying through the next downturn.